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Background. Time from acute stroke to enrolment in clinical trials needs to be reduced to improve the chances of finding effective
treatments. No completed randomised controlled trials of ambulance-based treatment for acute stroke have been reported in
the UK, and the practicalities of recruiting, consenting, and treating patients are unknown. Methods. RIGHT is an ambulance
based, single-blind, randomised controlled trial with blinded-outcome assessment. The trial will assess feasibility of using
ambulance services to deliver ultra-acute stroke treatments; a secondary aim is to assess the effect of glyceryl trinitrate (GTN) on
haemodynamic variables and functional outcomes. Initial consent, randomisation, and treatment are performed by paramedics
prior to hospitalisation. Patients with ultra-acute stroke (≤4 hours of onset) are randomised to transdermal GTN (5mg/24 hours)
or gauze dressing daily for 7 days. The primary outcome is systolic blood pressure at 2 hours. Secondary outcomes include
feasibility, haemodynamics, dependency, and other functional outcomes. A nested qualitative study is included. Trial Status. The
trial has all relevant ethics and regulatory approvals and recruitment started on February 15, 2010. The trial stopped recruitment in
December 2011 after 41 patients were recruited. Trial Registration. The trial registration number is ISRCTN66434824 and EudraCT
number is 2007-004766-40.
1. Background
Finding acute interventions which reduce early brain damage
and improve outcome after acute stroke is of major impor-
tance and has proved challenging. Irreversible brain damage
starts in the first minutes to hours after a stroke [1] and acute
stroke treatments can be highly time dependent; outcomes
after stroke thrombolysis are better when treatment is
given early [2]. Ambulance administration of emergency
treatment is standard in acute medical emergencies such
as acute myocardial infarction and asthma; thrombolysis
for MI was given 45 minutes earlier if administered in
an ambulance than at hospital [3]. Treatments for acute
ischaemic stroke (AIS) are not routinely administered prior
to hospital since current therapies reduce haemostasis (e.g.,
aspirin and alteplase) and need neuroimaging to exclude
primary intracerebral haemorrhage (PICH). However, other
potential treatments for acute stroke such as neuroprotection
and management of physiological disturbances (e.g., high
blood pressure [BP], hyperglycaemia and pyrexia) do not
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necessarily need prior neuroimaging and could be delivered
before hospitalisation. As benefits of such interventions
may be time dependent, prehospital administration could
considerably increase treatment efficacy by reducing onset to
treatment times.
One completed study (field administration of stroke
therapy-magnesium phase 3 clinical trial (FASTMag) pilot)
has assessed the feasibility of ambulance administration
of intravenous magnesium (a potential neuroprotectant)
[4]; this US open-label uncontrolled study found that
it was possible to enroll, consent, collect basic clinical
details, and administer treatment in 20 patients with acute
stroke (<12 hours of ictus) [5]. The main FASTMag
trial (http://www.fastmag.info/) is now running in Los
Angeles. In a different model of healthcare delivery in
ultra-acute stroke, scanning, diagnosis, and treatment may
be delivered at the emergency site using an ambulance
specifically equipped with computed tomography scanner,
point-of-care laboratory, and medical and nursing staff
[6, 7] However, no data are available on the practicality,
logistics (patient recruitment and paramedic involvement),
diagnostic accuracy, and consent issues of performing trials
in the UK ambulance environment in patients with ultra-
acute stroke. More studies are needed in prehospital stroke
care as highlighted at a European Commission Workshop in
2005 [8].
High blood pressure (BP > 140/90mmHg) is common
in AIS and PICH, and independently associated with a
poor outcome [9–11]. These observational data imply
that lowering an elevated BP could improve outcome,
providing cerebral blood flow (CBF) is not reduced in
the presence of dysfunctional autoregulation. However, a
Cochrane meta-analysis and a recently completed study
of angiotensin receptor antagonist (candesartan) in acute
stroke showed no evidence of benefit with drugs used to
deliberately alter blood pressure [12, 13]. While the results
of large ongoing trials such as ENOS [14] and INTERACT-
2 (http://clinicaltrials.gov/show/NCT00716079) are awaited,
these studies are hospital-based and cannot therefore recruit
patients in the ultra-acute period immediately after stroke
onset, and so cannot assess the safety and efficacy of immedi-
ate treatment. Administration of treatment prior to hospital,
for example, in the ambulance, would reduce delay providing
that treatment could be given to patients with either AIS or
PICH (i.e., treatment did not alter thrombosis/haemostasis)
and those with dysphagia (i.e., treatment did not require a
formal swallowing assessment and oral administration).
We have developed the use of transdermal GTN (5mg
per day, a nitric oxide donor) for lowering BP in acute
stroke in three pilot/phase II randomised controlled trials
[15–17]. Nitric oxide is a candidate treatment for stroke
being a key endogenous regulator of CBF and tissue
perfusion (in part through modulating pial vessel tone
thereby potentially improving collateral blood flow) and
has neuroprotective properties in experimental stroke [18].
Further, plasma NO levels (nitrate/nitrite) are low in acute
stroke and associated with a poor outcome [19, 20] so
supplementing NO in stroke might restore its normal
functions. The safety and efficacy of GTN is now being
tested in the ongoing MRC-funded “Efficacy of Nitric Oxide
in Stroke” (ENOS) trial (http://www.enos.ac.uk/), which is
also comparing the effect of continuing versus temporarily
stopping prior antihypertensive therapy. [14] ENOS has
recruited 3273 patients (as of September 14 2012).
We are assessing the feasibility of performing an
ambulance-based trial in patients with ultra-acute stroke, a
key question for the future testing of potential interventions
aimed at neuroprotection and physiological control, by
performing a randomised controlled trial comparing GTN
versus no GTN. The data relating to GTN will provide
further safety data for developing transdermal GTN as a
treatment modality in ultra-acute stroke.
2. Methods
2.1. Study Aims
2.1.1. Primary Aim. The primary aim is to assess the
feasibility of using ambulance service practitioners to assess
and deliver treatments for stroke in the ultra-acute setting
after stroke.
2.1.2. Secondary Aim. Assess the effect of GTN use in ultra-
acute stroke on safety, clinical, functional, and haemody-
namic outcomes.
Primary Objectives
(i) To report the proportion of randomised patients
with a final diagnosis of ischaemic stroke, primary
intracerebral haemorrhage, or transient ischaemic
attack.
(ii) To assess the additional time taken by research
paramedics for study related procedures prior to
hospital admission.
(iii) To report the experiences, perceptions, and chal-
lenges of a purposive sample of participating
paramedics in terms of approaching, consenting,
recruiting, and randomising patients to the trial.
(iv) To assess the proportion of patients randomised and
treated according to protocol.
(v) To assess the characteristics of patients screened by
the paramedics for inclusion to the RIGHT study.
(a) Proportion of patients screened by the
paramedics who were included in the study.
(b) Report the common reasons for failing the
study eligibility criteria.
(vi) To assess the characteristics of suspected acute stroke
patients admitted to the research sites.
(a) Proportion of suspected stroke patients who
satisfied the study eligibility criteria.
(b) Report the common reasons for failing the
study eligibility criteria.
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Secondary Objectives
(i) To assess the safety and tolerability of GTN in
suspected ultra-acute stroke.
(ii) To compare the difference in peripheral blood pres-
sure, central blood pressure, heart rate, and its
derivatives between patients randomised to GTN or
no GTN.
(iii) To compare the difference between GTN and noGTN
in death, disability, dependency, mood, cognition,
and quality of life.
2.2. Study Design. RIGHT is an ambulance-based, prospec-
tive, open label, single-blind, single city, randomised con-
trolled trial with blinded outcome assessment (Figure 1).
2.3. Study Setting. The study is conducted by the University
of Nottingham in collaboration with the East Midlands
Ambulance Service NHS Trust (EMAS) and Nottingham
University Hospitals (NUH) NHS Trust. Only patients who
are transported to the NUH Trust Hospitals (Nottingham
City Hospital, Queens Medical Centre Nottingham), which
provides service to approximately to 2.5 million residents of
Nottingham and its surrounding communities, are eligible
for recruitment. Research trained EMAS paramedics from
across 12 ambulances stations in Nottingham are taking part
in the study.
2.4. Study Population. Adult patients with suspected stroke
presenting to research trained paramedics and fulfilling the
following study criteria are eligible for recruitment.
2.4.1. Inclusion Criteria
(i) Adult male patients >40 years (to reduce the chance
of false positive strokes), female patients >55 years (to
exclude potentially pregnant patients).
(ii) Paramedic assessment of stroke on the basis of
positive “Face Arm Speech Test” (FAST) score of 2
or 3 [21, 22].
(iii) Event≤4 hours of onset (wake up stroke-onset as bed
time).
(iv) Systolic BP ≥140mmHg (any one of the two pre-
randomisation readings).
(v) Consent from patient, next of kin, or paramedic.
(vi) Patient being transported to RIGHT trial site.
2.4.2. Exclusion Criteria
(i) Definite need for GTN (e.g., concurrent angina).
(ii) Definite contraindication for GTN (e.g., dehydration,
hypovolaemia).
(iii) Nonambulatory prior to event onset.
(iv) Coma (Glasgow Coma Scale, GCS ≤8).
(v) Hypoglycaemia (blood glucose <2.5mmol/l).
(vi) Patients who are pregnant or breast feeding.
(vii) Systolic BP <140mmHg.
The limited exclusion criteria will result in a streamlined
trial with generalisable results (thereby providing external
validity).
2.5. Paramedic Training. Interested paramedics working for
the EMAS NHS Trust attended a training session on the
background, eligibility assessment, consent process and
study related procedures. A trial folder containing the trial
protocol, forms, and documents is maintained at all the 12
participating ambulance stations. Trial recruitment started
with 28 trained paramedics from 10 ambulance stations
in February 2010; a further 50 paramedics were trained
during the trial period to improve recruitment rate. Repeat
training sessions are conducted for paramedics who feel
a need to refresh their knowledge about the trial. All
paramedics were given information about the trial website—
http://www.right-trial.org/. Regular newsletters about the
trial status and important trial related information is sent to
all trained paramedics.
2.6. Screening, Recruitment, and Consent. The trial was active
during regular working hours from Monday to Friday.
During out of hours, trial paramedics contact the hospital
research staff if there is a potential patient, and recruitment
is allowed if hospital research staff are on site, available,
and able to perform trial related procedures. Weekend
recruitment from 0700 to 1500 hours was also allowed from
March 2011 depending on hospital research staff availability.
2.6.1. In the Ambulance. In the context of a “999” call for
suspected stroke, FAST score of >1, and assessment of study
eligibility, verbal consent is taken in the prehospital setting
by trained paramedics. Potential patients are approached by
the paramedic to take part in the study who explains the
trial to the patient by reading out a single page information
sheet. The sheet contains information on the purpose of the
study, reasons why they have been approached, and what will
happen to them if they take part. The research paramedic
then asks simple questions about the trial to assess if the
patient has understood the trial, that is, if they have the
capacity to give consent. These questions cover “what is your
diagnosis” (answer: stroke), “what is wrong with your blood
pressure” (answer: it is high), and “what is the treatment”
(answer: a patch) (G Ford, personal communication). If the
patient has understood the trial details and agrees to take part
in the study, they are then asked to sign a consent form.
For patients lacking capacity, their relatives, if present,
are approached to provide proxy-consent. If the patient is
unable to provide consent and there is no relative present,
research paramedics give proxy-consent on behalf of patients
for the first part of the trial provided a second paramedic or
ambulance technician acts as a witness to the consent process
and countersigns the form. The initial consent, from patient,
relative, or paramedic, covers the period in the ambulance
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Patient with suspected stroke calls
ambulance service
Assessment by research trained
paramedic
Patient fulfils inclusion and exclusion
criteria
Consent obtained for
first part of the trial by
research paramedic
Randomisation using prepacked
envelope
GTN + gauze dressing Gauze dressing
Research paramedic informs hospital
research staff about patient
Full informed consent
obtained by hospital
research staff
post randomisation BP, day 1 pulse
wave analysis, research bloods
BP and heart rate measured once daily
Day 3 (±1) pulse wave analysis
and research bloods
Day 7 (or death or discharge)
neurological impairment, stroke
recurrence, serious adverse events
Day 90 assessment of death, dependency,
disability, quality of life, cognition, and
mood.
heart rate by paramedic
15 minute post randomisation BP and
Hospital basline assessesments, 2 hour
Study intervention continued for 7 days.
Hospital discharge
diagnosis, discharge disposition
Hospital stay,
Figure 1: Trial flow chart.
(including administration of the first dose of treatment and
blood pressure measurement) up to and including admission
to hospital.
2.6.2. At Hospital. Once the patient arrives in hospital, the
hospital researcher discusses the trial, provides a full patient
information sheet, and answers any questions. If the patient
is unable to write (e.g., in the presence of dominant hand
weakness, ataxia, or dyspraxia), witnessed verbal consent
may be recorded on the consent form. If the patient lacks
capacity (e.g., in cases of dysphasia, confusion, or reduced
conscious level), proxy-consent is sought from a relative.
Full informed written consent is obtained from each patient
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within 24 hours of the initial consent, that is, before the
next treatment dose. If consent is not obtained within 24
hours, trial intervention is withheld after 24 hours but blood
pressure readings are taken until consent is obtained.
2.7. Randomisation. Each paramedic carries one or two
numbered opaque sealed envelopes in a transparent plas-
tic blue folder. The envelope contains trial paperwork
(described later) and a second opaque envelope that contains
a gauze dressing, with or without a single GTN patch (5mg);
this inner/second envelope is only opened if informed
consent is obtained. The research paramedic will not know
or be able to guess the treatment allocation prior to opening
the opaque envelope. This process amounts to simple
randomization with no stratification or minimisation.
2.8. Study Intervention
2.8.1. Investigational Medicinal Product (IMP). The study
intervention is transdermal glyceryl trinitrate (GTN) patch
(5mg) or none (control). GTN is given in the form of
Nitro-Dur 0.2mg/hr (Schering-Plough Ltd) with the patch
placed on the back or shoulder. Standard NHS supplies are
used. Since no companies manufacturing GTN patches were
willing to provide a placebo patch, the trial is open-label.
The GTN patch is covered with a gauze dressing. Similarly,
patients randomised to the control group have a gauze
dressing placed in a similar position to provide blinding of
treatment to the patient.
GTN patches are dispensed by Nottingham City Hospital
pharmacy. For prehospital use, the IMP is dispensed in a
numbered trial envelope sealed in a plastic transparent folder
containing gauze dressing with or without GTN patch along
with trial documents (ambulance information sheet, consent
forms, ambulance baseline case report form (CRF), inclusion
and exclusion criteria sheet, and a noninclusion form (to be
completed for patients who were screened but not included
in the trial)). The trial envelopes are stored in the drug
cupboard of participating ambulance stations. Each research
paramedic carries one or two envelopes when on duty after
signing a log sheet. The envelopes are picked up from the
ambulance station at the beginning of the shift (as with
opiates and cardiac thrombolytics) and returned at the end
of the shift.
In hospital, six gauze dressings with or without GTN
patches for each randomisation number are dispensed by the
pharmacy and kept in the acute stroke unit clinical trial drug
safe for hospital use. These are logged with batch number and
expiry date, and when they are given to patients.
2.8.2. Trial Treatment and Regimen. Trial treatment with
gauze dressing, with or without transdermal GTN patch
(5mg), is administered daily for 6 days (amounting to seven
treatments). Treatment is given on top of “best guideline
hospital care,” including alteplase (as appropriate after AIS)
and multimodal secondary prevention. Study medication
may be stopped if the patient withdraws consent, for safety
reasons, or if unacceptable adverse events develop. All prior
treatments may be continued at the discretion of the treating
physician.
2.9. Study Measures and Followup (Table 1). Peripheral blood
pressure measurements are performed using semiautomated
machines; the equipment varies in the ambulance whilst an
Omron 705CP or 705CP II is used in hospital [17]. All
measures are taken in duplicate in immediate succession.
Central blood pressure and aortic compliance are performed
in hospital using the pulse wave analysis (PWA) system
(Sphygmocor, Sydney, Australia) [16, 17]. Blood samples are
taken at baseline (EDTA and clotted) and on day 3 ± 1
(EDTA and clotted/serum). Serum and EDTA samples are
centrifuged prior to freezing and stored locally in a freezer
at −80 degree Celsius.
2.10. Protocol Violations. A protocol violation is a deviation
from the trial protocol where a patient is included outside
the inclusion/exclusion criteria for the trial, and where devi-
ations from the protocol could affect the trial significantly. A
list of violations is listed below.
(1) Male patient ≤40 years (to reduce the chance of
recruiting non-stroke patients and female patient
≤55 years (to avoid potential pregnant and child
bearing patients).
(2) Randomisation >4 hours from onset of symptoms.
(3) FAST score <2 at randomisation.
(4) Systolic BP <140mmHg at randomisation (neither of
the two readings).
(5) GCS ≤8 at randomization.
(6) Failure to obtain consent or proxy consent for patient
participation as specified in the protocol.
(7) Patient transferred to a nontrial site after randomisa-
tion.
(8) Patient was nonambulatory prior to symptom onset.
(9) Patient pregnant or breastfeeding.
(10) Definite need for GTN.
(11) Contraindication to GTN use.
(12) Blood glucose <2.5 at randomisation.
(13) Patient involved at time of randomisation or within 3
months in another medicinal clinical trial.
(14) Patient does not receive the first randomised treat-
ment.
(15) Hospital consent for continued participation in hos-
pital is not obtained within 24 hours of admission.
2.11. Nested Qualitative Study. We are systematically exam-
ining the experiences, perceptions, and challenges reported
by a purposive sample of 14 participating paramedics in
terms of approaching, consenting, recruiting, and ran-
domising patients to the trial; collaborative working with
researchers in an ultra-acute stroke trials; and implications
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Table 1: Study measures.
Event and timing (day) 1 3 ± 1 7 ± 1 Hospital discharge 90 ± 7
Randomisation +
Informed consent +
BP and heart rate∗ + + +
Scandinavian stroke scale (impairment) + +
Pulse wave analysis + +
Serious adverse events + + +
Diagnosis +
Disposition + +
Serum S-100 protein + +
Modified rankin scale + +
Barthel index +
Mini mental status examination +
EuroQOL +
Zung depression scale +
∗
BP and heart rate assessed daily till day 7.
for future studies. Semistructured interviews are being con-
ducted by S. Ankolekar, transcribed verbatim, and analysed
using thematic content analysis.
2.12. Pharmacovigilance. All adverse events are assessed for
their seriousness and causality to treatment by SA. A serious
adverse event (SAE) form is completed for each individual
SAE, as defined using standard definitions and reported
to the coordinating centre. All SAEs are reviewed by the
Chief Investigator (PB). Where an SAE is felt to fall under
the definition of a Suspected Unexpected Serious Adverse
Reactions (SUSAR), expedited reporting is made to the UK
Medicines and Health Regulatory Authority (MHRA) and
Research Ethics Committee.
2.13. Nontrial Patients. Case notes and ambulance report
forms of 41 consecutive patients admitted via the ambu-
lance services between September 2011 and January 2012,
directly to the Nottingham City Hospital Stroke Unit but
not recruited into the RIGHT study, and whose clinical
characteristics match the RIGHT study eligibility criteria, are
being reviewed to compare treatment and transfer timings
between those in the trial and those transferred into hospital
by a wider group of paramedics.
2.14. Outcome Measures
2.14.1. Primary. Comparison of systolic blood pressure at
2 hours post randomisation between GTN and no GTN
groups.
This outcome was chosen since it represents the sum of
the trial feasibility and intervention, that is, the ability to
identify, recruit, randomise, treat with GTN or control, and
make measurements in patients with ultra-acute presumed
stroke in an ambulance setting, and hand them over to
hospital staff. The 2 hour time reflects the time to peak effect
for GTN.
2.14.2. Secondary. Comparison between treatment groups.
Haemodynamic Effects
(i) BP, heart rate, and their derivatives (pulse pressure,
mean arterial pressure, peak pressure, trough pres-
sure, pressure variability, and rate pressure product)
on days 1–7.
(ii) Central BP and aortic compliance on days 1 and 3.
Functional and Clinical Outcome Measures during Treatment
(up to Day 7)
(i) Stroke impairment (Scandinavian Stroke Scale, SSS
[23], chosen as the results will be used to supplement
data from the ongoing ENOS trial that also uses the
SSS as the stroke severity scale.)
(ii) Neurological deterioration (Reduction in SSS score
>5 points between day 1 and day 7).
(iii) Recurrence.
(iv) Symptomatic intracranial events (haemorrhage and
mass effect).
(v) Major extracranial haemorrhage.
Hospital Events
(i) Discharge disposition.
(ii) Length of stay in hospital.
Day 90 (Final Followup)
(i) Dependency-modified Rankin scale (mRS) [24].
(ii) Disability (Barthel Index) [25].
(iii) Cognition (mini mental state examination) [26].
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(iv) Mood (Zung depression index, ZDI) [27].
(v) Quality of life (EuroQOL) [28].
Safety Outcomes
(i) Death, dependency, and neurological deterioration at
day 7.
(ii) Death at day 90.
(iii) Headache, hypotension, and hypertension at day 7.
(iv) Serious adverse events.
Ambulance Trial Logistics
(i) Recruitment rate per month.
Proportions of patients.
(i) Randomised: screened patients.
(ii) Treated according to protocol: all randomized.
(iii) Reasons for not enrolling (presence of exclusion
criteria and refusal of consent).
(iv) Final diagnosis of AIS, PICH, or transient ischaemic
attack: all randomized.
Timings. Trial patients
(i) Time from ictus to randomization.
(ii) Time from randomisation to hospital arrival.
(iii) Time from ictus to hospital arrival.
Comparison between trial and nontrial patients.
(i) Time from ictus to arrival by paramedics at scene of
ictus.
(ii) Time from paramedic arrival at scene of ictus to
hospital arrival.
(iii) Time from ictus to hospital arrival.
Blood samples
(i) Surrogate markers of efficacy (e.g., serum S-100
protein [29]).
3. Statistical Design and Analysis
3.1. Randomisation. Treatment allocation to the trial
envelopes was performed using a variable block size simple
randomisation with equal distribution between active and
control groups for the planned total of 80 patients.
3.2. Blinding. The study is single blind. There is no placebo
treatment in this trial. Trial treatment will be applied at a site
that is not easily visible to the patient (e.g., upper back). The
dressing will be changed each day to blind patients as to their
treatment allocation.
Bias will be reduced using multiple strategies: con-
cealment of allocation; patient blinding to GTN (gauze
dressing over patch); measurements and followup blinded
to treatment assignment; exclusion of patients enrolled in
other trials; analysis by intention-to-treat with adjustment
for nonrandomised treatment (alteplase).
3.3. Sample Size Calculation. Using data from our previous
clinical trials with GTN in acute stroke, and assuming alpha
(significance) = 5%, power (1-beta) = 90%, difference in SBP
at 2 hours 14 (SD 14)mmHg, and randomisation 1 : 1 for
GTN: control, a sample size of 80 will be needed. This sample
size should be sufficient to provide convincing evidence
on the utility and issues related to performing ambulance-
based trials, including diagnosis of stroke and additional
timing for research, of assessing the effect of GTN on BP. It
should be feasible to enrol 80 patients over 18 months (>1
patient/week).
3.4. Statistical Analysis. Data will be tabulated and described
as number (frequency %), median (interquartile range), or
mean (standard deviation). Data for each treatment group
(GTN versus no GTN) will be compared by intention-to-
treat. Unadjusted comparisons will be performed using chi-
square test (or Fisher’s exact test for data with small counts),
Mann-Whitney U test (ordered categorical data, e.g., mRS
[30] with correction for continuity and ties) and students
t test (continuous data, e.g., SBP). Comparison of systolic
blood pressure at 2 hours (primary outcome) between the
treatment groups will also be adjusted for baseline SBP, age,
and severity (SSS) (using ANCOVA); comparison of the mRS
at day 90 will be adjusted be for age, severity, stroke type, and
alteplase (using multiple regression) [31, 32].
4. Trial Regulation and Conduct
4.1. Ethics and Clinical Governance. The trial is being
conducted in accordance with the ethical principles that
have their origin in the Declaration of Helsinki (1996), the
principles of Good Clinical Practice (GCP), and the UK
Department of Health Research Governance Framework for
Health and Social care (2005). The trial has approvals from
the MHRA (reference 03057/0033/001-0001, dated Febru-
ary 16, 2009), Nottingham Research Ethics Committee-2
(reference 09/H0408/5, dated April 08, 2009), Research &
Development Departments at East Midlands Ambulance
Service (dated September 18, 2009) and NUH (reference
08SR003, dated September 30, 2009). The trial is sponsored
by the University of Nottingham (reference RIS 08022/30592,
dated January 12, 2009).
4.2. Service and User Involvement. The Nottingham Stroke
Patients forum discussed and supported the trial (dated
January 11, 2006) and members felt that they would have
been willing to take part if affected with a further stroke. The
trial has been presented to, and is supported by, the EMAS
board.
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4.3. Records and Data Protection. The investigator (S.
Ankolekar) and the local site pharmacist maintain records
of the study drug delivery. Each participant is assigned a
trial identity number, allocated at randomisation, for use on
case report forms (CRF) and other trial documents, and the
electronic database. All trial staff and investigators endeavor
to protect the rights of the trial’s participants to privacy and
informed consent and adhere to the Data Protection Act,
1998. CRFs are held securely, in a locked room, or locked
cupboard or cabinet.
4.4. Trial Conduct and Audit. Trial conduct is subject to audit
of the Trial Master File. Entries on CRFs are verified by
inspection against the source data. A sample of CRFs (10%)
is checked on a regular basis for verification of all entries
made. In addition the subsequent capture of the data on the
trial database will be audited. Where corrections are required
these will be subject to a full audit trail and justification.
Trial Status. RIGHT started recruiting patients in February
2010. Seventy-eight paramedics across 12 ambulance stations
were trained over the trial period to recruit patients. The trial
closed recruitment in December 2011 after 41 patients were
recruited and final followup was in March 2012. The results
will be submitted for publication later in 2012.
5. Discussion
The efficacy of thrombolysis with alteplase, the only licensed
treatment for AIS, is time dependent and most effective if
given within 3 hours [2]. Trials of putative neuroprotectant,
for example, magnesium and NXY-059, have failed univer-
sally. This may be because these drugs simply don’t work;
however the relatively long time windows for inclusion of up
to 6 or 12 hours may have contributed [4, 33]. Randomised
controlled trials of managing physiological disturbances in
acute stroke such as blood glucose and blood pressure have
not yet shown any benefit, but again they had long time
windows for recruitment [34, 35]. Hence, it is possible
that neuroprotection and physiological management may
also be time dependent and that these would be effective
if given within a few hours, as with alteplase [2]. Unlike
interventions that alter haemostasis, treatments that correct
physiological disturbances may be started before the patient
reaches the hospital prior to neuroimaging. However, no
data are available on the practicality, logistics, diagnostic
accuracy, and consent issues of performing trials in the
UK ambulance environment in patients with ultra-acute
stroke. This contrasts with the USA where ultra-acute
administration of magnesium has been reported in a small
uncontrolled study [4]; the large FAST-Mag trial is ongoing
and Germany where mobile stroke units reduce treatment
times in acute stroke patients [7].
The RIGHT study is assessing the feasibility of doing
ambulance based stroke trials in the UK. Our process of
proxy consent by the paramedics is novel and has not been
used previously. While this may not be standard practice, it is
vital to include patients with a range of clinical presentations,
including those with severe stroke, dysphasia, or reduced
consciousness; indeed it is the right of such patients to be
offered ultra acute treatment in the field. However, to ensure
validity of the consent process, such patients can only be
recruited provided another paramedic or technician acts as
a witness to the consent procedure.
The RIGHT trial will also provide important information
on the effects of GTN on haemodynamic variables in ultra-
acute stroke. The study, including the nested qualitative
work, will inform trial design for future larger randomised
controlled trials assessing efficacy of interventions correcting
physiological disturbances and neuroprotection in ultra-
acute stroke. Amulticentre trial of transdermal GTN in ultra-
acute stroke is already in design, subject to the findings of
RIGHT.
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